We are live on ! Find out more
RXII

GALENA BIOPHARMA INC COM
RXII

Delisted

RXII was delisted on the 25th of October, 2011.

85 hedge funds and large institutions have $44.3M invested in GALENA BIOPHARMA INC COM in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 27 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more call options, than puts

Call options by funds: $5.8M | Put options by funds: $4.94M

6% less funds holding

Funds holding: 9085 (-5)

11% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 27

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

36% less capital invested

Capital invested by funds: $68.9M → $44.3M (-$24.7M)

Holders
85
Holders Change
-5
Holders Change %
-5.56%
% of All Funds
2.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
24
Reduced
27
Closed
17
Calls
$5.8M
Puts
$4.94M
Net Calls
+$857K
Net Calls Change
+$398K
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$205K -$27.6K -13,400 -12%
RhumbLine Advisers
27
RhumbLine Advisers
Massachusetts
$205K -$4.33K -2,100 -2%
MLICM
28
Metropolitan Life Insurance Company (MetLife)
New York
$203K +$26.1K +12,643 +15%
TNB
29
Thomasville National Bank
Georgia
$195K
NFA
30
Nationwide Fund Advisors
Ohio
$190K +$1.46K +710 +0.8%
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$179K +$68.5K +33,269 +62%
AIG
32
American International Group
New York
$160K -$117 -57 -0.1%
AQR Capital Management
33
AQR Capital Management
Connecticut
$155K +$155K +75,000 New
CS
34
Credit Suisse
Switzerland
$151K +$24.4K +11,886 +19%
BA
35
BlackRock Advisors
Delaware
$150K -$2.69K -1,311 -2%
CCA
36
Castle Creek Arbitrage
Colorado
$132K
U
37
UBS
Switzerland
$123K -$74.1K -36,117 -38%
ProShare Advisors
38
ProShare Advisors
Maryland
$97K -$22K -10,629 -18%
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$94K
Principal Financial Group
40
Principal Financial Group
Iowa
$81K +$1.76K +855 +2%
PP
41
Paloma Partners
Connecticut
$78K +$78K +37,730 New
Ameriprise
42
Ameriprise
Minnesota
$71K +$55.4K +26,861 +356%
Bank of America
43
Bank of America
North Carolina
$67K -$87.7K -42,412 -57%
SG Americas Securities
44
SG Americas Securities
New York
$61K -$4.14K -2,007 -6%
DBIA
45
Dumont & Blake Investment Advisors
New Jersey
$61K
LTFS
46
Ladenburg Thalmann Financial Services
Florida
$59K -$10.7K -5,173 -15%
Jane Street
47
Jane Street
New York
$54K -$43.3K -21,085 -44%
Millennium Management
48
Millennium Management
New York
$50K -$17K -8,206 -25%
Legal & General Group
49
Legal & General Group
United Kingdom
$49K +$49K +23,219 New
GC
50
Guggenheim Capital
Illinois
$48K -$69.1K -33,994 -59%

RXII Hedge Fund Activity: Q3 2014 in Review

85 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in GALENA BIOPHARMA INC COM (RXII) for Q3 2014, worth a combined $44.3M — down 36% from $68.9M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RXII and 14 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 24 added.

The largest buyer was Morgan Stanley, adding an estimated $305K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $1.65M sold.

  • 85 institutional investors held GALENA BIOPHARMA INC COM (RXII) as of Q3 2014, down from 90 in Q2 2014.
  • Funds reported $44.3M of GALENA BIOPHARMA INC COM stock for Q3 2014, down 36% quarter-over-quarter.
  • 14 funds opened new GALENA BIOPHARMA INC COM positions in Q3 2014 and 17 closed out, a net change of -3 holders.
  • The largest GALENA BIOPHARMA INC COM buyer in Q3 2014 was Morgan Stanley, an estimated $305K added.
  • The largest GALENA BIOPHARMA INC COM seller in Q3 2014 was Bridgeway Capital Management, an estimated $1.65M sold.

Based on aggregated 13F filings for Q3 2014.